• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

22q11 微缺失综合征与超高精神病风险:神经软体征作为精神病易感性的独立标志物的作用。

22q11 microdeletion syndrome and ultra-high risk for psychosis: The role of neurological soft signs as an independent marker of vulnerability for psychosis.

机构信息

Department of Systems Medicine, Unit of Child Neurology and Psychiatry, "Tor Vergata" University of Rome, Rome, Italy.

Department of neuroscience, USL Umbria 2, Terni, Italy.

出版信息

Early Interv Psychiatry. 2019 Oct;13(5):1191-1198. doi: 10.1111/eip.12754. Epub 2018 Nov 26.

DOI:10.1111/eip.12754
PMID:30478947
Abstract

AIM

22q11 microdeletion syndrome has an increased risk for psychosis, similar to subjects at ultra-high risk for psychosis. Neurological soft signs are considered an endophenotype of psychotic disorders and a marker of vulnerability to Schizophrenia, consisting of overflow movements, dysrhythmia and speed of timed activities. To date, there are no studies that have evaluated the presence of the neurological soft signs in subjects with 22q11 microdeletion syndrome and there are a few studies that have analysed this issue in subjects at ultra-high risk.

METHODS

We sought to measure neurological soft signs in these two conditions, compared to healthy controls and to analyse the possible correlation between neurological soft signs and positive/negative symptoms both in 22q11 microdeletion syndrome and ultra-high-risk groups. 54 drug-naive patients (29 with 22q11 microdeletion syndrome and 25 at ultra-high risk for psychosis) and 25 healthy controls were evaluated for neurological soft signs.

RESULTS

Both clinical groups showed a greater number of neurological soft signs compared to healthy control, although the two clinical groups did not differ for the number of neurological soft signs. Positive correlation between speed of timed activities and negative symptoms was found in subjects at ultra-high risk.

CONCLUSION

Neurological soft signs could represent a marker of atypical neurodevelopment in the two populations examined. Since we did not found a strong correlation between neurological soft signs and positive/negative symptoms, we suggest that neurological soft signs could be indicators of vulnerability to psychosis independent from the psychopathology.

摘要

目的

22q11 微缺失综合征患者有较高的精神病发病风险,类似于精神病超高危人群。神经软体征被认为是精神障碍的一种内表型,也是精神分裂症易感性的标志物,包括溢出运动、节律紊乱和定时活动速度。迄今为止,尚无研究评估 22q11 微缺失综合征患者是否存在神经软体征,仅有少数研究分析了超高危人群中存在的神经软体征。

方法

我们试图在这两种情况下测量神经软体征,并与健康对照组进行比较,并分析 22q11 微缺失综合征和超高危组中神经软体征与阳性/阴性症状之间的可能相关性。我们评估了 54 名未接受药物治疗的患者(29 名患有 22q11 微缺失综合征,25 名处于精神病超高危状态)和 25 名健康对照组的神经软体征。

结果

与健康对照组相比,两个临床组的神经软体征数量均较多,但两个临床组的神经软体征数量没有差异。在超高危人群中,定时活动速度与阴性症状之间存在正相关。

结论

神经软体征可能代表了我们所研究的两个群体中神经发育异常的标志物。由于我们没有发现神经软体征与阳性/阴性症状之间存在强烈相关性,我们认为神经软体征可能是独立于精神病理学的精神病易感性的指标。

相似文献

1
22q11 microdeletion syndrome and ultra-high risk for psychosis: The role of neurological soft signs as an independent marker of vulnerability for psychosis.22q11 微缺失综合征与超高精神病风险:神经软体征作为精神病易感性的独立标志物的作用。
Early Interv Psychiatry. 2019 Oct;13(5):1191-1198. doi: 10.1111/eip.12754. Epub 2018 Nov 26.
2
Antipsychotics Do Not Influence Neurological Soft Signs in Children and Adolescents at Ultra-High Risk for Psychosis: A Pilot Study.抗精神病药物对处于超高精神病风险的儿童和青少年的神经软体征无影响:一项试点研究。
J Psychiatr Pract. 2019 May;25(3):186-191. doi: 10.1097/PRA.0000000000000387.
3
Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning.青少年超高精神病风险与 22q11 缺失综合征:前驱精神病症状和一般功能比较。
Schizophr Res. 2012 Aug;139(1-3):151-6. doi: 10.1016/j.schres.2012.04.020. Epub 2012 May 23.
4
No age effect in the prevalence and clinical significance of ultra-high risk symptoms and criteria for psychosis in 22q11 deletion syndrome: Confirmation of the genetically driven risk for psychosis?22q11缺失综合征中超高风险症状及精神病标准的患病率和临床意义不存在年龄效应:是否证实了精神病的遗传驱动风险?
PLoS One. 2017 Apr 13;12(4):e0174797. doi: 10.1371/journal.pone.0174797. eCollection 2017.
5
Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?精神分裂症发病前重度大麻使用:新的内表型的临床、认知和神经学证据?
Eur Arch Psychiatry Clin Neurosci. 2017 Oct;267(7):629-638. doi: 10.1007/s00406-017-0767-0. Epub 2017 Feb 11.
6
Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome.易患精神障碍的受试者的皮质形态学差异:超高风险受试者与22q11.2缺失综合征受试者的比较。
PLoS One. 2016 Nov 9;11(11):e0159928. doi: 10.1371/journal.pone.0159928. eCollection 2016.
7
Autism Spectrum and psychosis risk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study.22q11.2 缺失综合征中的自闭症谱系障碍和精神病风险。一项前瞻性纵向研究的结果。
Schizophr Res. 2017 Oct;188:59-62. doi: 10.1016/j.schres.2017.01.032. Epub 2017 Jan 21.
8
Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosis.探讨神经精神软体征在精神病超高危个体中的结构性脑关联。
Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1475-1485. doi: 10.1007/s00406-021-01300-9. Epub 2021 Aug 31.
9
Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis.22q11.2缺失综合征及超高精神病风险患者中独特的白质异常。
Psychol Med. 2016 Aug;46(11):2299-311. doi: 10.1017/S0033291716000970. Epub 2016 May 19.
10
Olfactory deficits and psychosis-spectrum symptoms in 22q11.2 deletion syndrome.22q11.2 缺失综合征患者的嗅觉缺陷与精神病谱系症状。
Schizophr Res. 2018 Dec;202:113-119. doi: 10.1016/j.schres.2018.07.012. Epub 2018 Jul 11.

引用本文的文献

1
Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis.儿童和青少年早发性精神病和精神病高危患者的阴性症状:系统评价和荟萃分析。
Br J Psychiatry. 2023 Jul;223(1):282-294. doi: 10.1192/bjp.2022.203.